Trial Profile
Extending Molecular Responses With Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients in Chronic Phase
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Aug 2023
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms ENESTxtnd
- Sponsors Novartis
- 15 Jun 2023 Results assessing he relationship between IVKI and subsequent molecular response using samples from the TIDEL-II study and ENESTxtnd study, presented at the 28th Congress of the European Haematology Association.
- 01 Oct 2017 Final results published in the British Journal of Haematology
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology